Equal-WT
WhaleScore 2.0
?
RA CAPITAL MANAGEMENT, L.P.
BOSTON MA
Investment Advisor
Hedge Fund
Activist Investor
RA Capital Management is based out of Boston. RA Capital Management is a hedge fund with 10 clients and discretionary assets under management (AUM) of $12,629,842,282 (Form ADV from 2025-03-31). Their last reported 13F filing for Q1 2025 included $5,987,912,728 in managed 13F securities
and a top 10 holdings concentration of 62.92%. RA Capital Management's largest holding is Ascendis Pharma A/S with shares held of 10,281,496. Whalewisdom has at least 75 13F filings, 176 13D filings, 756 13G filings, and 61 Form 4 filings
Business Description
Advisory Clients may have conflicting investment, tax, and other interests. These conflicts can arise from the nature of investments, structuring acquisitions, and timing dispositions, potentially leading to different returns for different clients. RA Capital will consider the investment and tax objectives of the Fund as a whole, not of individual Fund Investors.
Advisory Clients are typically not diversified and are concentrated in a small number of securities, sometimes with positions exceeding 15% of net asset value. This concentration can lead to material adverse impacts on a client’s capital if a single position experiences a loss. RA Capital may also establish separately managed accounts with individually negotiated terms and significant minimum investments.
Investment Strategy
RA Capital's investment strategies may include the use of investment techniques such as leverage, short sales, illiquid investments, and limited diversification. There is no guarantee that the Adviser’s investment strategies will be successful, or that the ultimate achievement of its investment objective will be profitable for Advisory Clients.
The Healthcare Funds make long and short investments, generally in publicly traded securities of or related to companies that may be based in the United States or other countries with substantial operations in healthcare and life sciences. The Healthcare Funds’ investment strategy most typically focuses on companies that develop drugs, research tools, diagnostics, or devices, and also sometimes purchase securities or short securities of companies that do not have substantial operations in healthcare and life sciences.
Owners
- PETER KOLCHINSKY REVOCABLE TRUST - PARTNER
- SAULNIER, MICHAEL - CHIEF FINANCIAL OFFICER
- ALDRICH, RICHARD, H. (MI ONLY) - PARTNER
- KOLCHINSKY, PETER, (NMN) - PORTFOLIO MANAGER
- GORGONE, CHRISTOPHER, LEE - HEAD OF CAPITAL FORMATION AND INVESTOR RELATIONS
- ROSE, ERIC, PAUL - CHIEF COMPLIANCE OFFICER
- REED, SARAH, WATT BURGESS - GENERAL COUNSEL
- SHAH, RAJEEV, MAHESH - PORTFOLIO MANAGER
- CALIRI, CHRISTOPHER, JAMES - CHIEF INFORMATION OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| ASND Ascendis Pharma A/S | 8.23% |
| SION Sionna Therapeutics | 1.82% |
| IRON Disc Medicine Inc | 1.31% |
| ETNB 89bio, Inc | 0.94% |
| MLYS Mineralys Therapeuti | 0.84% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| LEGN Legend Biotech Corp | 3.25% |
| XBI SPDR Biotech ETF | 1.47% |
| AXSM Axsome Therapeutics | 1.13% |
| VRNA Verona Pharma Plc | 1.09% |
| PRAX Praxis Precision Med | 0.78% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| ASND Ascendis Pharma A/S | 26.76% |
| PCVX Vaxcyte, Inc | 7.69% |
| RYTM Rhythm Pharmaceutica | 5.38% |
| JANX Janux Therapeutics I | 5.05% |
| NAMS NewAmsterdam Pharma | 3.47% |
The shares of Climb Bio, Inc. listed in the Information Table with "OTR" investment discretion represent shares held by Sera Medicines, LLC ("Sera"). Funds advised by the Reporting Manager collectively own approximately 76.60% of the outstanding equity interests of Sera that would share in distributions of the shares of Climb Bio, Inc. or proceeds derived therefrom. Investment discretion with respect to the shares held by Sera is shared with individuals not affiliated with the Reporting Manager.
2025-03-31
13F Activity
| Market Value | $5.99b, Prior: $7.51b |
| Inflows (Outflows) as % of Total MV | +1.6268% |
| New Purchases | 11 stocks |
| Added To | 14 stocks |
| Sold out of | 15 stocks |
| Reduced holdings in | 4 stocks |
| Top 10 Holdings % | 62.92% |
| Turnover %[1] | 26% |
| Turnover Alt %[2] | 12.2% |
| Time Held Top 20 | 6.1 quarters |
| Time Held Top 10 | 6.6 quarters |
| Time Held All | 6.96 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31